Withaferin A and Checkpoint Blocker Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune checkpoint blocker therapies for lung cancer are limited by immune resistance, affecting only 20% of patients, necessitating the development of combination therapies that overcome resistance without additive toxicity.
Innovation Solution
Administering withaferin A in combination with immune checkpoint inhibitors, such as PD-1 or PD-L1 blockers, to enhance immune cell infiltration and activation, thereby sensitizing tumors to therapy and overcoming resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint blockers are used alone, then treatment simplicity is maintained, but treatment efficacy is limited to only 20% of patients due to immune resistance
Solution Approach 1:
The patent combines withaferin A (a natural compound) with immune checkpoint blockers (monoclonal antibodies) to create a combination therapy. This merging of two different therapeutic agents addresses immune resistance while maintaining a manageable treatment protocol, thereby improving treatment efficacy without excessive complexity
Solution Approach 2:
Withaferin A acts as an intermediary agent that modifies the tumor microenvironment and enhances immune cell function, thereby mediating between the immune checkpoint blocker and the resistant tumor cells. This intermediary approach allows the immune checkpoint blocker to overcome resistance mechanisms
2Reliability
If combination therapies are developed to overcome immune resistance, then treatment efficacy is improved, but additive toxicity may increase
Solution Approach 1:
The patent utilizes withaferin A to induce parameter changes in the tumor microenvironment, including modification of immune cell activation states and tumor cell susceptibility. These parameter changes enable immune checkpoint blockers to achieve therapeutic effects at potentially lower doses, reducing additive toxicity
Solution Approach 2:
The patent converts the normally harmful immunosuppressive tumor microenvironment into a beneficial setting for immune activation. Withaferin A transforms resistant tumor cells and suppressive microenvironmental factors into conditions that enhance immune checkpoint blocker efficacy while minimizing additional toxicity
3Reliability
If withaferin A is combined with immune checkpoint inhibitors, then immune cell infiltration and activation are enhanced, but treatment protocol complexity increases
Solution Approach 1:
The patent employs withaferin A to perform preliminary actions on the tumor microenvironment and immune cells before administering immune checkpoint blockers. This preliminary conditioning of the microenvironment and immune cells enhances subsequent immune checkpoint blocker efficacy, allowing for a more streamlined overall protocol
Data Source
AI summary
The present disclosure provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of withaferin A and an immune checkpoint blocker. Further, the cancer to be treated may be resistant, have developed resistance, or may be susceptible to resistance to treatment with the immune checkpoint blocker alone or in combination with another therapeutic agent other than withaferin A.